Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Gamida Cell's share price for the quarter that ended in Mar. 2024 was $0.0361. Gamida Cell's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 154.05 Mil. Therefore, Gamida Cell's market cap for the quarter that ended in Mar. 2024 was $5.56 Mil.
Gamida Cell's quarterly market cap
declined
from Sep. 2023 ($135.89 Mil) to Dec. 2023 ($59.61 Mil) and
declined
from Dec. 2023 ($59.61 Mil) to Mar. 2024 ($5.56 Mil).
Gamida Cell's annual market cap
declined
from Dec. 2021 ($152.32 Mil) to Dec. 2022 ($96.21 Mil) and
declined
from Dec. 2022 ($96.21 Mil) to Dec. 2023 ($59.61 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Gamida Cell's Enterprise Value for Today is $55.93 Mil.
Gamida Cell Market Cap Historical Data
The historical data trend for Gamida Cell's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gamida Cell's Market Cap
For the Biotechnology subindustry, Gamida Cell's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gamida Cell's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gamida Cell's Market Cap distribution charts can be found below:
* The bar in red indicates where Gamida Cell's Market Cap falls into.
Gamida Cell Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Gamida Cell's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gamida Cell (OTCPK:GMDAQ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Gamida Cell Market Cap Related Terms
Thank you for viewing the detailed overview of Gamida Cell's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GMDAQ has been successfully added to your 